Almost all of them are still long way to go before becoming commercial products, if at all. Does it look like they run off with it as you asserted? Or do they have to shoulder the development cost and risk?
One of the drugs is of course their COVID vaccine which is a home run. It’s the potential of such windfall that makes them willing to bet on all of the other drugs in the pipeline.
You cited Cuba’s COVID vaccine. How many other drugs do they have in pipeline? Right, not so many compared to all of the drugs developed by private money. Ask yourself, with regard to their COVID vaccine, how extensive was the testing? can they scale the production? how widely can they distribute the vaccine?
Cuba has a fairly large biomedical sector and export industry, despite being under crushing sanctions. It’s absurd to ask about the scale of their development relative to private industry in the US because it’s impossible for them to even gain access to the same raw materials. But that’s also entirely beside the point because the discussion was about whether we need to allow Moderna to rake in billions off public investment in basic research and IP rentiering in order to make COVID vaccines possible. The example of the Cuban vaccine disproves this, but all the pharma apologists of course prefer to talk circles around this point instead of addressing it.
